Biotechnology
The company has informed the market of its purchase of own shares in accordance with the authority granted at the Annual General Meeting held on July 17, 2025. A total of 258,841 Ordinary shares of 25p each were purchased today for cancellation at a price of 829.37 pence
Biotechnology
Concord Biotech, a leading biopharmaceutical company, has seen a significant rise in stock prices after incorporating a wholly owned subsidiary company, Concord Lifegen. With a current market capitalization of Rs. 20,297.64 crore, the company's stock price has touched a high of Rs. 1945.00 and a
Biotechnology
The Company, an entity listed on the London Stock Exchange, has announced that it has made market purchases of its own shares, specifically purchasing a total of 48,514 Ordinary shares of 25p each at a price of 802.37 pence per share. This move comes under the authority granted
Biotechnology
The UK-based company has made a market purchase of its own ordinary shares, with 76,993 shares being bought at a price of 752.67 pence per share. This purchase is part of the company's authorized share buyback program, which allows it to purchase up to 4,255,
Biotechnology
The Biotech Growth Trust PLC has issued a notification regarding its market purchase of its own shares. The company has been authorized to make market purchases up to an aggregate maximum of 4,255,299 shares. Recent transactions have seen a total of 470,069 Ordinary shares of 25p each
Biotechnology
The Biotech Growth Trust PLC has initiated a market purchase program to buy back its own shares up to an aggregate maximum of 4,255,299. As part of this program, the company has purchased a total of 151,422 ordinary shares of 25p each for cancellation. This transaction brings
Biotechnology
A British company based in London has made a market purchase of its own ordinary shares, with 75,000 shares being bought back for cancellation at a price of 747.63 pence per share. This transaction brings the company's total issued shares to 26,066,844, with no
International cooperation
Hong Kong's Director of the Hong Kong Economic and Trade Office in New York, Ms Maisie Ho, visited Boston to strengthen ties with the city's biotechnology, research, and academic sectors. During her visit, Ms Ho highlighted Hong Kong's status as a global hub for
International cooperation
Ocugen, a biotechnology company, will present at the 2025 BIO International Convention, where the company's leadership team will engage with potential partners and pharmaceutical executives to explore opportunities for its modifier gene therapy platform targeting major blindness diseases. The company has achieved significant milestones, including FDA alignment for
International cooperation
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced that Robb Knie, Chief Executive Officer, will attend the BIO International Convention in Boston, MA, from June 16-19, 2025. The convention represents the largest and most comprehensive event for biotechnology, with 20,000 industry leaders from across the globe. Hoth Therapeutics is a
Securities law
Lexaria Bioscience Corp., a Nevada-based company, has filed a Form 8-K with the U.S. Securities and Exchange Commission on June 12, 2025, announcing the entry into a Change Order with Novotech (Australia) Pty Limited. This Change Order amends the terms of the Project Agreement (PA) between Lexaria Bioscience Corp.
Securities law
Shareholders of Zivo Bioscience, Inc. gathered at the annual meeting on June 9, 2025, where they voted to approve the election of two Class III directors, the reappointment of BDO USA, P.C. as the company's independent registered public accounting firm, and the compensation of the company'
